Symbols

HIND

Vyome·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About HIND

Vyome Holdings, Inc.

Emerging AI biopharmaceutical companies in the clinical stage of the US stock market

Industry

Pharmaceutical

Established Date

01/02/2008

Listing Date

10/06/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.vyometx.com

Security Type

Common stock

Office address

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

Business

Introduction

Vyome Holdings, Inc., was incorporated on January 2, 2008 under the laws of the State of Delaware. The company is a clinical-stage specialty pharmaceutical company headquartered in the United States and India, focusing on the development of next-generation treatments for immune inflammation and rare diseases. Its main project, VT-1953, is a topical gel for malignant fungal wounds, while the company also sells commercialized antifungal products in India through a license agreement.

Company Financials

EPS

HIND has released its 2025 Q1 earnings. EPS was reported at 19.52, versus the expected 0, beating expectations. The chart below visualizes how HIND has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

HIND has released its 2025 Q4 earnings report, with revenue of 36.55K, reflecting a YoY change of -40.50%, and net profit of -1.28M, showing a YoY change of -317.44%. The Sankey diagram below clearly presents HIND's revenue sources and cost distribution.